WHO vaccine-preventable diseases: monitoring system. 2017 global summary

Last updated 15-July-2017 (data as of 11-July-2017)
Next overall update Fall-2017
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 1 Infant (under 12 months) mortality rate: 22
GDP / capita (US$): 1 Child (under 5 years) mortality rate: 32

Population data in thousands3

  2016  2015  2014  2013  2012  2000  1990  1980 
Total population 77  78  79  81  82  65  55  36 
Births
Surviving infants
Pop. less than 5 years
Pop. less than 15 years 11  12  12  12  12  10  11 
Female 15-49 years 17  18  18  19  20  17  14 

Number of reported cases

(Click for retrospective incidence data for Andorra)
Diphtheria
ChartChart
 
Japanese encephalitis
 
Measles
ChartChart ChartChart
 
Mumps
ChartChart
 
Pertussis
ChartChart
  16 
Polio*
ChartChart
 
Rubella
ChartChart
 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Andorra)
Vaccine year result method % card seen                                                
BCG         
DTP1         
DTP3          98  97  97  96  99  98 
DTP4          95  95  96 
IPV1         
HepB_BD          94  94  94  96 
HepB3          94  94  96  94  97  84 
Hib3          98  97  97  96  98  90 
JapEnc         
MCV1          97  96  96  95  98  97 
MCV2          90  88  90  91  89 
MenA         
PCV1         
PCV2         
PCV3          92  92  93 
Pol3          98  97  97  97  99  95 
Rota1         
RotaC         
RCV1          97  96  96  95  98 
TT2plus         
PAB         
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid-July 2018

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Andorra)
DTP1
ChartChart
  99  99  99  98  99  99 
DTP3
ChartChart
  98  97  97  96  99  98 
HepB3
ChartChart
  94  94  96  94  97  84 
HepB_BD
ChartChart
  94  94  94  96  95 
Hib3
ChartChart
  98  97  97  96  98  90 
MCV1
ChartChart
  97  96  96  95  98  97 
MCV2
ChartChart
  90  88  90  91  89 
PCV3
ChartChart
  92  92  93 
Pol3
ChartChart
  98  97  97  96  99  95 
RCV1
ChartChart
  97  96  96  95  98  97 
RotaC
 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2016 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DTaPHibHepIPV 2, 6, 12 months; Yes
HepB_Pediatric birth; Yes
HPV 12 years; +6 months; Yes
Influenza_Adult => 65 years; Yes and pregnant women, health care workers, adults with chronic diseases, travellers and other risk groups
Influenza_Pediatric Yes children with chronic diseases
MenB 2, 4, 13 months; Yes
MenC_conj 4, 15 months; 12 years; Yes
MMR 12 months; 3 years; Yes
Pneumo_conj 3, 5, 13 months; Yes
TdaPIPV 5, 15 years; Yes
Varicella 15 months; 3 years; Yes

Immunizaton indicators

Indicator Expected answer 2016  2015  2014  2013  2012  2011  2010 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2015-2017  2015-2017           
Nº of districts with microplans that include activities to raise immunization coverage number  

System performance

Total Nº districts in country number    
Nº districts with DTP3 coverage >=80% number            
% of districts with DTP3 coverage >=80% From 0 to 100%              
Nº districts with measles (MCV1) coverage >=95% number            
% of districts with MCV1 coverage >=95% From 0 to 100%              

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND No  No    Yes  Yes  Yes  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100% 100  100  100  100  100  100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2015
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.